ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1636

Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study

Renaud DESBARBIEUX, 59037, CHRU de Lille, Lille, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: remission, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant proportion of patients. However, few data are available to determine the feasibility of decrease of a biological DMARD and define the strategy once remission is achieved.

Methods:  This retrospective multicenter study have included patients with rheumatoid arthritis treated with tocilizumab (8mg/kg every 4 weeks) for at least 6 months and who have been a decrease dose for reasons of efficacity. Data were collected in major hospitals in the region Hauts-de-France, 3 months, 6 months and 12 months after reducing tocilizumab (study conducted between 1 January 2010 and 31 December 2015).

Results:  337 patients were included in the analysis. 48 patients had a decrease because of efficacity. All of them were in DAS remission (DAS28 < 2.6) with a mean DAS28 CRP 1.55. 42 patients had a dose reduction to 4mg/kg, when 6 patients had a spacing of the infusions every 6 weeks. At 12 months, the median ΔDAS was 0.49 (p = 0.0002). DAS28 CRP usual dose group was higher than in the Efficacy group (2.99 vs 2.12, p <0.0001). 30 patients (70%) were able to maintain remission (61%) or low dose activity (9%). 4 patients have a DAS28 CRP higher than 3.2 at 12 months. 7 patients (16%) resumed tocilizumab 8mg/kg every 4 weeks before the end of the follow. In case of resumption of tocilizumab in usual dose, there was no significant difference between the initial DAS28 and DAS28 at 3 months (p = 0.1563 and 0.2197) and 6 months of recovery (p = 0.8125 and 0.8984). There was no significant increase of methotrexate or corticosteroids (p <0.0001). The initial weight, a long period of remission before decrease, a low DAS28 CRP appeared predictive of favorable response at 12 months (p = 0.016, 0.012 and 0.0032).

Conclusion:  Our study demonstrates the feasibility, safety and efficacy of tocilizumab decrease dose (from 8 to 4mg/kg), to maintain remission or low activity in a majority of patients without concomitant increase in corticosteroids or conventional DMARD.


Disclosure: R. DESBARBIEUX, None;

To cite this abstract in AMA style:

DESBARBIEUX R. Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/decrease-of-tocilizumab-in-rheumatoid-arthritis-in-remission-a-multicenter-study/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decrease-of-tocilizumab-in-rheumatoid-arthritis-in-remission-a-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.